ALFA Finder| Revenue growth | Consolidated revenue flat at ₹345.4 cr; standalone exports down 23%. |
|---|---|
| Margins | EBITDA margins expanding significantly through high-margin complex generics and branded products. |
| Order book | Order book stands at ₹171 cr, supporting standalone recovery expectations. |
| Demand visibility | Strong order book of ₹171 cr provides visibility for FY27 growth. |
| Management confidence | Balanced; focused on inflection point following regulatory clearances and facility upgrades. |
Growth
Consolidated EBITDA jumped 485% to ₹15.8 cr, driven by Inoxxel narrowing losses. Verineum turned profitable, growing 13.7% YoY.
Outlook
FY27 guidance: 10-15% growth for standalone, 35-45% for Inoxxel, and 20-25% for Verineum with expanded margins.
Risks
Standalone business faces temporary disruption from plant upgrades and upcoming PIC/S and EUGMP audits in FY27.
Earnings Call filed with BSE, BSE: 541096. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,839.20
- Market cap
- ₹1,268 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- 1019.1×Sector 43.8×
- Promoter holding
- 67.20%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Earnings Call Transcript: Key Takeaways
Q2 FY27 consolidated revenue ₹136.3 Cr (+110% YoY, +45% QoQ) and PAT ₹11.8 Cr, the first group profit quarter, led by Innoxel. Standalone margins squeezed by input costs; FY27 guidance maintained.
Bharat Parenterals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹136.3 Cr (+110.9% YoY), EBITDA ₹23.6 Cr (17.3%), PAT ₹11.8 Cr; Innoxel turned profitable.
Bharat Parenterals Q2 FY27 Results: Turns Profitable, Net Profit ₹11.8 Cr
Bharat Parenterals approved unaudited standalone results for the quarter ended 30 September 2026. The company reported profit and revenue growth versus the prior-year quarter.
- Key figure
- Net profit ₹11.8 Cr
Bharat Parenterals Board Meeting Date
Bharat Parenterals will hold a board meeting on October 29, 2026 to consider unaudited standalone and consolidated results. Trading window has been closed since October 1, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals held an EGM via video conferencing on October 23, 2026. Members considered a preferential equity issue and Section 186 investment and guarantee limits.
Bharat Parenterals Business Update
Innoxel Lifesciences, a Bharat Parenterals subsidiary, began U.S. commercial supply of its first CMO product. This adds recurring manufacturing revenue to its existing licensing income.